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K e y  M e s s a g e s 
1. S proteins of both SARS-CoV and HCoV-HKU1 
share a similar profile of unfolded protein 
response (UPR)–activating activity. They 
activate the production of UPR effector proteins 
Grp78/94 and to a lesser extent CHOP through 
PERK kinase. 
2. S proteins of SARS-CoV and HCoV-HKU1 have 
distinct UPR-activating domains. Whereas the 
UPR-activating activity requires the central 
region (amino acids 201-400) of the S1 subunit in 
SARS-CoV, the corresponding part in the HCoV-
HKU1 S protein does not induce endoplasmic 
reticulum stress or UPR. 
3. Suppression of type I interferon (IFN) production 
is a unique property of SARS-CoV M protein. 
HCoV-HKU1 M protein does not inhibit the 
Modulation of cell signalling by human 
coronavirus HKU1 S and M proteins
DY Jin *, PCY Woo
Introduction
In 2003, an outbreak of severe acute respiratory 
syndrome (SARS) occurred in Hong Kong and 
spread worldwide. The SARS coronavirus (SAR-
CoV) caused a highly lethal disease and disproved 
the concept that human coronaviruses are generally 
associated with mild respiratory disease. Another 
new coronavirus—HCoV-HKU1—that circulates 
commonly in the human population and causes 
relatively milder respiratory tract illness worldwide 
was also discovered.1 The mechanism by which 
SARS-CoV and HCoV-HKU1 cause respiratory 
diseases of different severity remains elusive. 
Variations in their ability to modulate cell signalling 
and innate immunity might be influential.2
 Human coronaviruses are enveloped and 
positive-stranded RNA viruses with a large genome. 
They hijack the endoplasmic reticulum (ER) to 
process their structural and non-structural proteins 
produced in extraordinarily large amounts. They 
also need to circumvent the production and function 
of type I interferons (IFNs), major effectors of 
innate antiviral immunity. We have demonstrated 
the capability of SARS-CoV S protein to induce 
ER stress and to activate the unfolded protein 
response (UPR).3 We have also found that SARS-
CoV M protein suppresses innate IFN production 
by impeding the formation of a functional complex 
of tumour necrosis factor receptor-associated factor 
3 (TRAF3) - TRAF family member-associated 
NF-κB activator (TANK) - TANK-binding kinase 
Hong Kong Med J 2016;22(Suppl 4):S22-4
RFCID project number: 10091192
1 DY Jin, 2 PCY Woo
The University of Hong Kong:
1 School of Biomedical Sciences
2 Department of Microbiology
* Principal applicant and corresponding author: dyjin@hku.hk
1(TBK1)/ inhibitor of nuclear factor κB kinase 
subunit ε (IKKε).4 In the present study, we set out to 
determine whether HCoV-HKU1 S and M proteins 
homologous to their counterparts in SARS-CoV 
might have similar properties. We also mapped the 
functional domains in SARS-CoV S and M proteins 
that are required for their respective UPR-activating 
and IFN-antagonising activity. 
Methods
This study was conducted from January 2011 to 
December 2012. HCoV-HKU1 may be cultured 
in primary human ciliated airway epithelial cells.5 
Nonetheless, success was limited and the virus 
remains unculturable in most laboratories. Lack of 
an infectious clone of HCoV-HKU1 further hampers 
functional analysis. At this stage, mechanistic 
studies could only be performed through analysis of 
cloned HCoV-HKU1 S and M genes as well as their 
mutants. Therefore, all experiments were carried out 
with cultured HEK293 or 293FT cells transiently 
transfected with expression vectors for SARS-
CoV and HCoV-HKU1 S and M proteins or their 
truncated mutants.
Results
UPR activation by SARS-CoV and HCoV-
HKU1 S proteins
We have reported the activation of binding 
immunoglobulin protein (Grp78) and heat shock 
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES
innate IFN response. 
4. IFN antagonism of SARS-CoV M protein is 
ascribed to its first transmembrane domain 
(TM1) situated at the N terminus. TM1 targets M 
protein to the Golgi complex and interacts with 
TRAF3 and other transducer proteins to prevent 
the formation of a functional TRAF3-containing 
multi-component complex.
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protein 90kDa beta member 1 (Grp94) promoters 
by SARS-CoV S protein.2 Grp78 and Grp94 are 
robust UPR markers. They function as molecular 
chaperones and are swiftly induced in the UPR. We 
found that the transcriptional activity driven by the 
Grp94 promoter was stimulated to a similar extent 
by S proteins of both SARS-CoV and HCoV-HKU1 
(Fig 1). HCoV-HKU1 S protein activated the Grp94 
promoter in a dose-dependent manner and with equal 
potency when compared with SARS-CoV S protein. 
For another comparison, β-galactosidase was also 
overexpressed. The activity of Grp94 promoter was 
minimally or very mildly affected by this large foreign 
protein. Similar results were obtained with the 
Grp78 promoter and to a lesser extent with the DNA 
damage-inducible transcript 3 (C/EBP homologous 
protein; CHOP) promoter. Activation of Grp78 and 
Grp94 promoters by S proteins required eukaryotic 
translation initiation factor 2-alpha kinase 3 (PERK) 
kinase. Thus, S proteins from both coronaviruses 
exhibited similar activity to induce ER stress and to 
activate UPR signalling.
Definition of UPR-activating domain in S 
protein of SARS-CoV
SARS-CoV S protein is proteolytically processed 
into S1 and S2 subunits. To determine whether 
the S1 (amino acids 1-770) or S2 (amino acids 771-
1255) subunit is required for UPR activation by 
SARS-CoV S protein, we compared them side by 
side for activation of Grp78 and Grp94 promoters. 
The activity of Grp78 and Grp94 promoters was not 
affected by S2, but induced fully by S1. To compare 
with HCoV-HKU1 S protein, the cleavage of which 
inside cells remains uncertain, similar regions 
matching the S1 and S2 subunits of SARS-CoV S 
protein were interrogated for their ability to activate 
Grp78 and Grp94 promoters. Neither S1 nor S2 
of HCoV-HKU1 was capable of activating these 
promoters. The UPR-activating domain in SARS-
CoV S1 subunit was further dissected to the central 
region (amino acids 201-400).
Suppression of type I IFN production by M 
protein of SARS-CoV, but not HCoV-HKU1
We have demonstrated that SARS-CoV M protein 
is capable of antagonising type I IFN production.3 
To assess whether HCoV-HKU1 M protein behaves 
similarly, we compared the two M proteins for their 
ability to induce IFN-β. We used mitochondrial 
antiviral-signalling protein (MAVS), a mitochondrial 
adaptor protein that transmits the activation signal, 
to boost IFN production. The steady-state level 
of IFN-β transcript in transfected HEK293 cells 
FIG 1.  Activation of UPR signalling by S proteins: 293FT cells 
were transfected with the indicated pGrp94-Luc luciferase 
reporter and expression constructs. Cells were harvested 
36 hours after transfection and dual luciferase assay was 
performed. Amounts of expression plasmids for lacZ and 
S proteins were progressively increased. Relative luciferase 
activity was derived from readouts of firefly luciferase activity 
normalised to readouts of Renilla luciferase activity. Activity 
recovered from cells receiving lacZ vector alone was set as 
1. Results represent means from triplicate experiments with 
error bars indicating the SD (Reproduced with permission 























FIG 2.  Inhibition of IFN-β production by M protein of 
SARS-CoV (SARS-M) but not of HCoV-HKU1 (HKU1-M): 
HEK293 cells were transfected with the indicated plasmids 
and harvested at 30 hours after transfection. Real-time 
RT-PCR was carried out to quantify the levels of IFN-β 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
transcripts. A fixed amount of MAVS expression vector and 
progressively escalating amounts of SARS-M and HKU1-M 
expression plasmids were used. Relative expression levels 
of IFN-β mRNA were derived from 2Ct(GAPDH)-Ct(IFN-β) and 
normalised to levels from cells mock-transfected with empty 
expression vector, which were set as 100% (Reproduced 
with permission from the Cell and Bioscience and the 
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expressing or not expressing SARS-CoV and HCoV-
HKU1 M proteins was then monitored by real-time 
RT-PCR. Interestingly, M protein of SARS-CoV but 
not of HCoV-HKU1 mitigated the IFN-inducing 
activity of MAVS (Fig 2). Similar results were also 
obtained with RIG-I and TBK1. Additional luciferase 
reporter assays lent further support to the notion 
that suppression of IFN production by M protein is 
specific to SARS-CoV and not seen in HCoV-HKU1. 
IFN antagonism is mediated through TM1 of 
SARS-CoV M protein 
Three transmembrane domains (TM1: 1-38 amino 
acids; TM2: 51-69 residues; and TM3: 76-85 
residues) followed by a cytoplasmic endodomain 
(86-221 amino acids) are found in SARS-CoV M 
protein. To map the IFN-antagonising domain in 
SARS-CoV M protein, a series of truncated mutants 
designated M1, M2, TM1′, TM2′ and TM3′ were 
constructed and tested in a stepwise approach. 
First, the three TMs in M1 were indispensable for 
the suppression of IFN production by SARS-CoV 
M protein. Second, TM1 of the three TMs was 
absolutely required for IFN antagonism. Among the 
three mutants named TM1′, TM2′ and TM3′, which 
respectively contain TM1 (amino acids 1-38), TM2 
(amino acids 51-69) and TM3 (amino acids 76-85) 
domains fused to the endodomain for the purpose of 
maintaining protein stability, only TM1′ was able to 
suppress IFN-β promoter activity activated by RIG-I, 
MAVS or TBK1. Neither TM2′ nor TM3′ showed 
any IFN-antagonising activity. Since TM2, TM3 and 
endodomain were not required for IFN antagonism, 
only TM1 was essential and probably sufficient for 
the suppressive effect on IFN production.
Discussion
We compared the UPR-activating and IFN-
antagonising activities of S and M proteins of SARS-
CoV and HCoV-HKU1. The two S proteins displayed 
a similar profile of UPR-activating properties with 
the ability to activate Grp78, Grp94 and CHOP 
promoters but not UPR element enhancer. The two 
S proteins also possessed a distinct UPR-activating 
domain. The S1 subunit of SARS-CoV sufficed to 
activate the UPR, but no UPR-modulating activity 
was seen in its counterpart in HCoV-HKU1. 
Although SARS-CoV and HCoV-HKU1 S proteins 
had distinct UPR-activating domains, they exerted 
similar modulatory effects on UPR signalling. 
 Our findings on the activation of UPR by 
SARS-CoV and HCoV-HKU1 S proteins have 
important implications for therapeutic intervention. 
Pharmaceutical UPR modulators have been 
developed and extensively tested for diseases 
including viral infection. Inhibition of PERK 
kinase has a negative impact on cytomegalovirus 
replication, but a small-molecule UPR activator 
also displays broad-spectrum antiviral activity. In 
this regard, our analysis of the activation of UPR 
by S proteins might lay the foundation for further 
assessment of the utility of UPR modulators for the 
treatment of SARS and HCoV-HKU1 infection.
 SARS-CoV M protein does not share its IFN-
antagonising property with HCoV-HKU1 M protein. 
Its IFN antagonism is mediated by the TM1 domain 
(amino acids 1-38), which targets it to the Golgi 
apparatus where it associates with TRAF3 to impede 
the interaction with TBK1 and IKKε. Our findings 
provide additional molecular details for suppression 
of IFN production by SARS-CoV M protein. Our 
definition of a small TM1 domain that mediates 
immune evasion will pave the way for rational 
design and development of new immunosuppressive 
agents. In this regard, both peptide mimetics and 
recombinant proteins that mimic the action of TM1 
might prove useful.
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